Kite Pharma, Inc.
KITE
KITE was delisted on the 2nd of October, 2017.
244 hedge funds and large institutions have $8.88B invested in Kite Pharma, Inc. in 2017 Q3 according to their latest regulatory filings, with 105 funds opening new positions, 52 increasing their positions, 67 reducing their positions, and 80 closing their positions.
130% more funds holding in top 10
Funds holding in top 10: 10 → 23 (+13)
69% more capital invested
Capital invested by funds: $5.24B → $8.88B (+$3.64B)
31% more first-time investments, than exits
New positions opened: 105 | Existing positions closed: 80
11% more funds holding
Funds holding: 220 → 244 (+24)
22% less repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 67
28% less call options, than puts
Call options by funds: $453M | Put options by funds: $628M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CI
Cowen Inc
New York
|
+$585M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$197M |
| 3 |
TCSAM
Tyrus Capital S.A.M.
Monaco
|
+$183M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$136M |
| 5 |
Renaissance Technologies
New York
|
+$108M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$719M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$339M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$243M |
| 4 |
Capital World Investors
Los Angeles,
California
|
-$202M |
| 5 |
Capital International Investors
Los Angeles,
California
|
-$155M |
KITE Hedge Fund Activity: Q3 2017 in Review
244 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Kite Pharma, Inc. (KITE) for Q3 2017, worth a combined $8.88B — up 69% from $5.24B a quarter earlier.
Buyers outnumbered sellers: 105 funds opened new KITE positions and 80 closed out — a net gain of 25 holders — while 52 added to existing stakes and 67 trimmed.
The largest buyer was Cowen Inc, opening a new position worth an estimated $585M. The largest seller was Capital Research Global Investors, exiting entirely with an estimated $719M sold.
- 244 institutional investors held Kite Pharma, Inc. (KITE) as of Q3 2017, up from 220 in Q2 2017.
- Funds reported $8.88B of Kite Pharma, Inc. stock for Q3 2017, up 69% quarter-over-quarter.
- 105 funds opened new Kite Pharma, Inc. positions in Q3 2017 and 80 closed out, a net change of +25 holders.
- The largest Kite Pharma, Inc. buyer in Q3 2017 was Cowen Inc, an estimated $585M added.
- The largest Kite Pharma, Inc. seller in Q3 2017 was Capital Research Global Investors, an estimated $719M sold.
Based on aggregated 13F filings for Q3 2017.